Search Results - "Salloway, Stephen"

Psychometric and adherence considerations for high-frequency, smartphone-based cognitive screening protocols in older adults.

Authors: Thompson, Louisa I. De Vito, Alyssa N. Kunicki, Zachary J. et al.

Source: Journal of the International Neuropsychological Society; Oct2024, Vol. 30 Issue 8, p785-793, 9p

Longitudinal post-shunt outcomes in idiopathic normal pressure hydrocephalus with and without comorbid Alzheimer's disease.

Authors: Gold, Dov Wisialowski, Caroline Piryatinsky, Irene et al.

Source: Journal of the International Neuropsychological Society; Oct2023, Vol. 29 Issue 8, p751-762, 12p

Glial Vascular Degeneration in CADASIL.

Authors: Brennan-Krohn, Thea Salloway, Stephen Correia, Stephen et al.

Source: Journal of Alzheimer's Disease. 2010, Vol. 21 Issue 4, p1393-1402. 10p.

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease.

Authors: Salloway, Stephen Lee, Elly Papka, Michelle et al.

Source: BJPsych Open. 2024 Supplement, Vol. 9, pS67-S67. 1p.

Frontal Behavior Syndromes in Idiopathic Normal Pressure Hydrocephalus as a Function of Alzheimer's Disease Biomarker Status.

Authors: Niermeyer, Madison Gaudet, Chad Malloy, Paul et al.

Source: Journal of the International Neuropsychological Society; Oct2020, Vol. 26 Issue 9, p883-893, 11p

Are Blood Tests for Alzheimer Disease Ready for Prime Time?

Authors: Salloway, Stephen Rowe, Christopher Burns, Jeffrey M.

Source: JAMA: Journal of the American Medical Association. 10/15/2024, Vol. 332 Issue 15, p1240-1241. 2p.

Clinical and Pathological Examples of Alzheimer's Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia.

Authors: Salloway, Stephen¹

Source: Medicine & Health Rhode Island. Jul2012, Vol. 95 Issue 7, p207-209. 3p.

Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning.

Authors: Castillo-Barnes, Diego Su, Li Ramírez, Javier et al.

Source: Information Fusion; Jun2020, Vol. 58, p153-167, 15p

Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes.

Authors: Asken, Breton M. Thomas, Kelsey R. Lee, Athene et al.

Source: Journal of the International Neuropsychological Society; May2020, Vol. 26 Issue 5, p464-479, 16p

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.

Authors: Pontecorvo, Michael J Devous, Michael D Kennedy, Ian et al.

Source: Brain: A Journal of Neurology; Jun2019, Vol. 142 Issue 6, p1723-1735, 13p

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

Authors: Vöglein, Jonathan Paumier, Katrina Jucker, Mathias et al.

Source: Brain: A Journal of Neurology; May2019, Vol. 142 Issue 5, p1429-1440, 12p

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Authors: Caballero, Miguel Ángel Araque Suárez-Calvet, Marc Duering, Marco et al.

Source: Brain: A Journal of Neurology; Oct2018, Vol. 141 Issue 10, p3065-3080, 16p

91 Remote Smartphone-Based Assessment Predicts Standard Neuropsychological Test Performance and Cerebral Amyloid Status in Cognitively Normal Older Adults.

Authors: Thompson, Louisa I. Strenger, Jennifer R. Emrani, Sheina et al.

Source: Journal of the International Neuropsychological Society; 2023 Supplement, Vol. 29, p493-494, 2p

28 Variability in Remote, Self-Administered Assessment Performance Associated with Self-Reported Memory Perceptions Among Older Adults.

Authors: Strenger, Jennifer R. Riera, Natalie Harrington, Karra et al.

Source: Journal of the International Neuropsychological Society; 2023 Supplement, Vol. 29, p340-341, 2p

48 Psychometric properties of DCTclock™ with commonly used neuropsychological tests and their combined ability to predict Beta-Amyloid Positron Emission Tomography Status.

Authors: Emrani, Sheina Strenger, Jennifer Kunicki, Zachary et al.

Source: Journal of the International Neuropsychological Society; 2023 Supplement, Vol. 29, p255-256, 2p

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.

Authors: Salloway, Stephen P. Sperling, Reisa Fox, Nick C. et al.

Source: Journal of Alzheimer's Disease. 2018, Vol. 64 Issue 3, p689-707. 19p.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Authors: Pontecorvo, Michael J. Devous Sr, Michael D. Navitsky, Michael et al.

Source: Brain: A Journal of Neurology; Mar2017, Vol. 140 Issue 3, p748-763, 16p

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Authors: Lim, Yen Ying Hassenstab, Jason Cruchaga, Carlos et al.

Source: Brain: A Journal of Neurology; Oct2016, Vol. 139 Issue 10, p2766-2777, 12p

Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test.

Authors: Wolk, David Salloway, Stephen Dickerson, Brad

Source: JAMA: Journal of the American Medical Association. 6/18/2019, Vol. 321 Issue 23, p2289-2291. 3p.

Alzheimer's disease.

Authors: Scheltens, Philip Blennow, Kaj Breteler, Monique M. B. et al.

Source: Lancet. 7/30/2016, Vol. 388 Issue 10043, p505-517. 13p.

Subjects: Alzheimer's disease research, Disease prevalence, Disease incidence, Dementia, Amyloid, Alzheimer's disease diagnosis, Alzheimer's disease prevention, Brain metabolism, Alzheimer's disease, Behavior, Brain, Cognition, Deoxy sugars, Magnetic resonance imaging, Nerve tissue proteins, Peptides, Radiopharmaceuticals, Positron emission tomography, Systematic reviews, Psychology